Related Experiment Video

Updated: May 20, 2025

Culture of Bladder Cancer Organoids as Precision Medicine Tools
08:39

Culture of Bladder Cancer Organoids as Precision Medicine Tools

Published on: December 28, 2021

4.5K

Subtypes and Sequencing in Bladder Cancer: Powering Personalised Treatment or Extraneous Information?

Ella Schofield1, James W F Catto1, Jon Griffin2

  • 1Academic Urology Unit, School of Medicine and Population Health, University of Sheffield, Sheffield, UK; Urology Department, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.

European Urology
|May 17, 2025
PubMed
Summary

No abstract available in PubMed .

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.4K
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

14.7K

Related Experiment Videos

Last Updated: May 20, 2025

Culture of Bladder Cancer Organoids as Precision Medicine Tools
08:39

Culture of Bladder Cancer Organoids as Precision Medicine Tools

Published on: December 28, 2021

4.5K
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.4K
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

14.7K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K

Articles linked to this work by shared authors, journal, and citation graph.

INtraVESical immunoTherapy (INVEST) prior to radical cystectomy for bladder cancer: trial protocol.

BJU international·2026

State of the nation: Understanding the current NHS treatment pathway to identify opportunities to advance future care of patients with high-risk non-muscle invasive bladder cancer in the UK (SPAN-UK).

BJUI compass·2026

Comprehensive genome-wide association study into multiple recurrence and progression risk in non-muscle invasive bladder cancer.

Cancer genetics·2026

Update of the EORTC Health-related Quality of Life Modules for Bladder Cancer: Phase 1-2 of the Development Process.

European urology oncology·2026

Artificial Intelligence Remote Patient Monitoring for Predicting Overall Survival for Patients Undergoing Radical Cystectomy for Bladder Cancer: Exploratory Analysis of the Prospective Trial.

JMIR AI·2026

International Survey of Thromboprophylaxis Practices During Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer.

Clinical genitourinary cancer·2026

EORTC 2238 DE-ESCALATE: Revisiting Intermittent Maximal Androgen Blockade in Metastatic Hormone-sensitive Prostate Cancer.

European urology·2026

Influence of Adverse Pathologic Features on Potential Benefit of Hormone Therapy Use with Postoperative Radiotherapy in Recurrent Prostate Cancer: An Individual Patient Data Meta-analysis.

European urology·2026

Cystectomy Can Be Spared in Selected Patients with Muscle-invasive Bladder Cancer and Complete Response Following Neoadjuvant Therapy.

European urology·2026

Systematic Review and Meta-analysis on Renal Tumor Biopsy: Accuracy, Safety, and Impact on Clinical Decision-making.

European urology·2026

What Comes After Matters: The Importance of Postprogression Care in Patients with Metastatic Hormone-sensitive Prostate Cancer.

European urology·2026

Patient-reported Outcomes After Prostate Stereotactic Body Radiotherapy at 5 yr: Results from the PACE-B Trial.

European urology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us